Cell-cultured quadrivalent influenza vaccines may have greater effectiveness compared with standard, egg-derived quadrivalent influenza vaccines.
Targeting the elderly (individuals aged 65 years) for influenza vaccination may not decrease hospitalization or mortality rates in this population.
In laboratory-confirmed cases of COVID-19, patients with any comorbidities have experienced poorer clinical outcomes compared with those without comorbidities.
Hospitalized patients withCOVID-19 had higher proportions of nonproductive cough, fatigue, and gastrointestinal symptoms as well as lower severity of illness scores compared with patients with H1N1 influenza.
The observed intra-seasonal decreases of measured influenza vaccine effectiveness was only partially accounted for by leaky vaccine bias.
Wearing face masks could be slightly protective against primary infection with influenza-like illness from casual community contact.
Hospitalization due to influenza leads to a high likelihood of readmission within 30 days and 1 year with cardiovascular, respiratory, and infectious etiologies being the most common.
The adjuvanted, broad-spectrum influenza vaccine FLU-v was found to be immunogenic and merits phase 3 development to explore efficacy.
Researchers determined the risk for Guillain-Barré Syndrome following seasonal influenza vaccination in a real-world study.
Baloxavir inhibits the endonuclease activity of the polymerase acidic protein resulting in inhibition of influenza virus replication.
Implementation of an influenza immunization program increased vaccinations rates from 44% to 57% the following year.
Early neuraminidase inhibitor therapy may result in better outcomes in patients hospitalized with influenza B-related pneumonia.
The FDA has approved Fluad Quadrivalent for active immunization in patients 65 years of age and older against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine.
No difference was seen in the risk for serious neuropsychiatric events in patients who received oseltamivir in the 30 days after influenza diagnosis compared with those who did not.
Despite the higher effectiveness of the quadrivalent inactivated influenza vaccine against the added B virus lineage, trivalent inactivated influenza vaccine.
Compared with patients prescribed only an antiviral, patients who are prescribed both an antiviral and antibiotic have a lower risk for 3-day respiratory hospitalization.
The CDC continues to recommend influenza vaccination as the best method of protection while the viruses are circulating in the community.
Black people who are HIV-positive may have a decreased ratio of influenza-specific IgG vs IgM after influenza vaccination.
A double-dose of inactivated influenza vaccine may not increase the immunogenicity of the vaccine among pregnant women with HIV.
The FDA has approved influenza A [H5N1] monovalent vaccine for active immunization for the prevention of disease in patients 6 months of age and older at increased risk of exposure to the influenza A H5N1 virus subtype contained in the vaccine.